Dimensional Fund Advisors LP Acquires 273,890 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)

Dimensional Fund Advisors LP increased its holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 103.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 538,900 shares of the company's stock after acquiring an additional 273,890 shares during the period. Dimensional Fund Advisors LP owned about 1.02% of Stoke Therapeutics worth $5,943,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Bank of New York Mellon Corp boosted its holdings in shares of Stoke Therapeutics by 1.4% during the fourth quarter. Bank of New York Mellon Corp now owns 93,195 shares of the company's stock worth $1,028,000 after purchasing an additional 1,330 shares during the period. Rhumbline Advisers increased its stake in Stoke Therapeutics by 6.0% in the 4th quarter. Rhumbline Advisers now owns 49,374 shares of the company's stock valued at $545,000 after buying an additional 2,787 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Stoke Therapeutics by 29.2% during the 4th quarter. JPMorgan Chase & Co. now owns 19,964 shares of the company's stock valued at $220,000 after buying an additional 4,512 shares during the period. Wells Fargo & Company MN grew its holdings in shares of Stoke Therapeutics by 51.2% during the 4th quarter. Wells Fargo & Company MN now owns 16,786 shares of the company's stock valued at $185,000 after acquiring an additional 5,682 shares in the last quarter. Finally, KLP Kapitalforvaltning AS purchased a new position in shares of Stoke Therapeutics during the 4th quarter valued at $63,000.

Insider Buying and Selling at Stoke Therapeutics

In related news, insider Barry Ticho sold 3,884 shares of the company's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $33,674.28. Following the completion of the transaction, the insider now directly owns 63,962 shares in the company, valued at $554,550.54. This represents a 5.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Edward M. Md Kaye sold 10,382 shares of the firm's stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $90,011.94. Following the completion of the sale, the director now owns 148,253 shares in the company, valued at $1,285,353.51. This represents a 6.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 16,532 shares of company stock valued at $143,332 in the last 90 days. 11.30% of the stock is currently owned by insiders.

Stoke Therapeutics Price Performance

STOK traded up $0.20 on Friday, hitting $9.83. The company had a trading volume of 186,002 shares, compared to its average volume of 711,648. The stock has a market cap of $536.42 million, a price-to-earnings ratio of -4.66 and a beta of 1.20. The company's fifty day moving average price is $8.12 and its 200 day moving average price is $9.99. Stoke Therapeutics, Inc. has a 1-year low of $5.35 and a 1-year high of $17.58.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last posted its earnings results on Monday, March 24th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.56) by $0.38. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The business had revenue of $22.61 million for the quarter, compared to analyst estimates of $4.20 million. On average, sell-side analysts forecast that Stoke Therapeutics, Inc. will post -2.01 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on STOK shares. HC Wainwright cut their price objective on Stoke Therapeutics from $47.00 to $35.00 and set a "buy" rating for the company in a report on Wednesday. Needham & Company LLC reaffirmed a "buy" rating and set a $22.00 price target on shares of Stoke Therapeutics in a research note on Wednesday, April 9th. Chardan Capital reissued a "buy" rating and issued a $24.00 price target on shares of Stoke Therapeutics in a research note on Wednesday, March 19th. Finally, Cantor Fitzgerald raised shares of Stoke Therapeutics to a "strong-buy" rating in a research report on Wednesday. Five analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $23.20.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.